Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion
Daniel Guilfoyle(Royal Prince Alfred Hospital), Michael Barnett(The University of Sydney), Tomáš Kalinčík(The Royal Melbourne Hospital), Helmut Butzkueven(The Alfred Hospital), E O Lui(The Royal Melbourne Hospital), Anneke van der Walt(The Alfred Hospital), Izanne Roos(The Royal Melbourne Hospital), Yael Barnett(St Vincent's Hospital Sydney), Nathaniel Lizak(The Alfred Hospital), Heidi Beadnall(Royal Prince Alfred Hospital), Bianca Weinstock‐Guttman(Jacobs Institute), Robert Zivadinov(Yale University), K Buzzard(Box Hill Hospital), Chenyu Wang(Wuhan University), Kayla Ward(Royal Prince Alfred Hospital), Andy Shieh(Cooperative Trials Group for Neuro-Oncology), Olga Skibina(Box Hill Hospital), Alexander Klistorner(The University of Sydney), M.G. Dwyer(Buffalo Psychiatric Center), Meng Law(The Alfred Hospital), Samuel Klistorner(The University of Sydney)
Cited by 0
Related Papers
Multiple Sclerosis Severity Score
|Neurology|2005|957
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative
|Nature Reviews Neurology|2016|413
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
|The Lancet Neurology|2025|314
Diagnosis and classification of optic neuritis
|The Lancet Neurology|2022|290